Cytomegalovirus Reactivation in Critically-ill COVID-19 Patients

Autor: Leyla Talan, İrem Akdemir Kalkan, Neslihan Defne Altıntaş, Fügen Yörük

Publikováno v: Balkan Medical Journal, Vol 39, Iss 4, Pp 301-302 (2022)

Externí odkaz: https://doaj.org/article/414234e1a59c401fa791a954e3c50367

SARS-CoV-2 Infection may be Prevented with Cytochrome Inhibitors: Cobicistat and Ritonavir

Autor: Ismail Çelik, Ezgi Gülten, Arzu Onay-Besikci, Güle Çınar, Irem Akdemir-Kalkan, Gülgün ılcıgil, K. Osman Memikoglu, M. Serhat Birengel, Alpay Azap

Publikováno v: Infectious Diseases and Clinical Microbiology. 4:185-191

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec415134c5e83472934b32668ce7cd2e
https://doi.org/10.36519/idcm.2022.139

Evaluation of the Effects of Different Antibiotic Combinations on Multi-Drug Resistant Gram-Negative Bacteria

Autor: Güle Çınar, Zeynep Bayındır, İrem Akdemir Kalkan, Aysun Yalçı, Hüseyin Kutlu, Devran Gerçeker, Haluk Güriz, İsmail Balık

Publikováno v: Journal of Ankara University Faculty of Medicine. 75:28-35

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f14832cdffd58b83b6a2141266fd638f
https://doi.org/10.4274/atfm.galenos.2021.60565

A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

Autor: Emine Begum Gencer-Oncul, Guldane Cengiz Seval, Ezgi Gülten, Hasan Yalim Akin, Meral Beksac, Mahsa Yousefzadeh, Güle Çınar, Osman Memikoglu, İrem Akdemir Kalkan, Klara Dalva, Ergun Karaagaoglu

Publikováno v: Immunogenetics

Graphical abstract Associations between inherited Killer Immunoglobulin-like Receptor (KIR) genotypes and the severity of multiple RNA virus infections have been reported. This prospective study was initiated to investigate if such an association exi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4cd5516a6ca378512cc9d30766e55fb
http://europepmc.org/articles/PMC8449213

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Autor: Mine Durusu Tanriover, Hamdi Levent Doğanay, Murat Akova, Hatice Rahmet Güner, Alpay Azap, Sıla Akhan, Şükran Köse, Fatma Şebnem Erdinç, Emin Halis Akalın, Ömer Fehmi Tabak, Hüsnü Pullukçu, Özgür Batum, Serap Şimşek Yavuz, Özge Turhan, Mustafa Taner Yıldırmak, İftihar Köksal, Yeşim Taşova, Volkan Korten, Gürdal Yılmaz, Mustafa Kemal Çelen, Sedat Altın, İlhami Çelik, Yaşar Bayındır, İlkay Karaoğlan, Aydın Yılmaz, Aykut Özkul, Hazal Gür, Serhat Unal, Bircan Kayaaslan, İmran Hasanoğlu, Ayça Dalkıran, Ömer Aydos, Güle Çınar, İrem Akdemir-Kalkan, Ahmet Çağkan İnkaya, Mehtap Aydin, Hatice Çakir, Jale Yıldız, Özenir Kocabıyık, Sonay Arslan, Bayram Nallı, Ömer Demir, Sarp Singil, Çiğdem Ataman-Hatipoğlu, Günay Tuncer-Ertem, Sami Kınıklı, Uğur Önal, Bilgül Mete, Gözde Dalgan, Meltem Taşbakan, Tansu Yamazhan, Berna Kömürcüoğlu, Enver Yalnız, Aysun Benli, Çağla Keskin-Sarıtaş, Mustafa Gökhan Ertosun, Özlenen Özkan, Salih Emre, Seçil Arıca, Ferit Kuşçu, Aslıhan Candevir, Buket Ertürk-Şengel, Fadime Ayvaz, Firdevs Aksoy, Çiğdem Mermutluoğlu, Yakup Demir, Gülşah Günlüoğlu, Seda Tural-Önür, Ayşin Kılıç-Toker, Esma Eren, Barış Otlu, Ayşe Özlem Mete, Kübra Koçak, Hale Ateş, İlkay Koca-Kalkan, Kurtuluş Aksu

Publikováno v: Lancet (London, England)

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c968a18aabe68eea102421fdd0bbec9c
http://europepmc.org/articles/PMC8266301